Flow cytometry has traditionally been used for the analysis of individual samples. Our invention, HyperCyt uses a peristaltic pump in combination with an autosampler to boost throughput (see References 1- 13 in Center Overview). As the sampling probe moves from well to well, a peristaltic pump sequentially aspirates particle suspensions from each well. Between wells, the pump draws a bubble of air into the sample line resulting in the delivery of a series of bubble-separated samples. The time-resolved data, with periodic gaps corresponding to the passage of the sample-separating air bubbles, are analyzed by our software. When the MLI began, we had screened only 96 well plates, but proposed to move to a fully automated 384 well system. We routinely screen 384 well plates with multiplexed data sets in 10-12 min with sample volumes of 1- 2 u,l, even for multiplexed samples. Complete systems integration has proven elusive in part because flow cytometry companies had been reluctant, except for Luminex which provided an SDK, to provide access to proprietary control software which allows integration of our sampling system with the flow cytometer. (Although we have shown that Luminex 20 plexes are compatible with NTS, the cost of Luminex reagents ~$0.10 per well per singleplex even at a deep bulk discount would add $250,000 to the cost of screening a sixplex against a library of 500,000 compounds.) We have recently solved this generic control problem by creating our own software that controls third party flow cytometry programs via the Windows API (application programming interface) and by collaborating with LANL to implement a free standing data acquisition system, ORCAS. We are now in a position to use our expertise and tools to develop a fully integrated HT flow cytometry system and to overcome the limitations of flow cytometry to complement fully automated technologies in the MLPCN. We will: 1) overcome the throughput barrier by rapid sampling from 1536 well plates;2) overcome the fluid carryover limitation that arises from sampling through long tubing via a peristaltic pump in front of the sample chamber;3) overcome the limitation of cell compression and activation by the peristaltic pump;4) overcome the limitation of dilute samples when adherent cell populations are resuspended in 384 or 1536 well plates. By the end of 4 years, we will integrate these elements into several, robust automated platforms that include sample plate thermal control and particle resuspension, allowing NTS flow cytometry to take its place in the armamentarium of robust HTS capabilities for the MLPCN and for the international scientific community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54MH084690-04S1
Application #
8443192
Study Section
Special Emphasis Panel (ZRG1-IFCN-K)
Project Start
2012-03-20
Project End
2014-05-31
Budget Start
2012-03-20
Budget End
2013-05-31
Support Year
4
Fiscal Year
2012
Total Cost
$98,311
Indirect Cost
$25,522
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Hong, Lin; Chavez, Stephanie; Smagley, Yelena et al. (2016) Relationship of light scatter change and Cdc42-regulated actin status. Cytometry B Clin Cytom 90:499-505
Yang, Jeremy J; Ursu, Oleg; Lipinski, Christopher A et al. (2016) Badapple: promiscuity patterns from noisy evidence. J Cheminform 8:29
Zahoránszky-Kőhalmi, Gergely; Bologa, Cristian G; Oprea, Tudor I (2016) Impact of similarity threshold on the topology of molecular similarity networks and clustering outcomes. J Cheminform 8:16
Wu, Yang; Stauffer, Shaun R; Stanfield, Robyn L et al. (2016) Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair. J Biomol Screen 21:74-87
Sykes, David B; Kfoury, Youmna S; Mercier, François E et al. (2016) Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell 167:171-186.e15
Guo, Yuna; Kenney, S Ray; Cook, Linda et al. (2015) A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients. Clin Cancer Res 21:5064-72
Magana, Maria; Ioannidis, Anastasios; Magiorkinis, Emmanouil et al. (2015) Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections. Curr Pharm Des 21:2058-72
Schreiber, Stuart L; Kotz, Joanne D; Li, Min et al. (2015) Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell 161:1252-65
Edwards, Bruce S; Sklar, Larry A (2015) Flow Cytometry: Impact on Early Drug Discovery. J Biomol Screen 20:689-707
Guo, Yuna; Kenney, S Ray; Muller, Carolyn Y et al. (2015) R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther 14:2215-27

Showing the most recent 10 out of 108 publications